Annual report pursuant to Section 13 and 15(d)

Stockholders' equity - Additional information (Detail)

v3.22.2.2
Stockholders' equity - Additional information (Detail)
6 Months Ended 12 Months Ended
Apr. 30, 2021
$ / shares
shares
Oct. 06, 2020
$ / shares
shares
Apr. 22, 2020
shares
Dec. 31, 2020
shares
Jun. 30, 2022
USD ($)
$ / shares
shares
Jun. 30, 2021
USD ($)
$ / shares
shares
Dec. 06, 2019
shares
$ / shares
Unrecognised share based compensation expense | $         $ 522,000 $ 1,266,000  
Term of warrants             5 years
weighted-average grant-date fair value of stock options granted | $ / shares         $ 2.6 $ 2.68  
Common Stock [Member]              
Warrants convertible into shares of common stock on exercise     107,095        
Cashless exercise of purchase warrants (In shares)     37,417   37,417 37,417  
Purchase Warrants [Member]              
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares             $ 10.5
Number of series of warrants issued             4
Expiry date of warrants             Dec. 06, 2024
Warrants convertible into shares of common stock on exercise             214,190
IPO [Member]              
Sale of Stock, Number of Shares Issued in Transaction   2,666,644          
Sale of stock issue price per share | $ / shares   $ 3.1          
Over-Allotment Option [Member]              
Sale of Stock, Number of Shares Issued in Transaction 317,274 483,870          
Sale of stock issue price per share | $ / shares $ 4.25 $ 3.1          
Pre-funded warrants [Member]              
Sale of Stock, Number of Shares Issued in Transaction 3,036,366     559,162      
Sale of stock issue price per share | $ / shares $ 4.25 3.09          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares   $ 0.01          
Number of Warranrs exercised           559,162